Restrictions on experimental treatments will likely have a significant impact on pharmaceutical companies which have, in recent years, bought up rights to experimental drugs created in China

A fresh crackdown on the country's medical and pharmaceutical sectors, set to last a year, has convinced investors that it may be best to buy the state and sell private sector holdings